Nucor Corporation vs Nuwellis Inc — how do they compare? Nucor Corporation trades at $230.8 (market cap $52.55B), while Nuwellis Inc trades at $2.94 (market cap $1.09M). The key difference: Nucor Corporation is far larger — about 48211× Nuwellis Inc's market cap, and Nucor Corporation pays a 0.97% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.
| NUE | NUWE | |
|---|---|---|
Market Cap | $52.55B | $1.09M |
Sector | Basic Materials | Technology |
52-Week High | $266.35 | $527.46 |
52-Week Low | $131.78 | $2.80 |
Enterprise Value | $57.19B | -$722.58K |
Dividend Yield | 0.97% | — |
Signals from Pluang's Aura AI — not financial advice
Nucor (NUE) trades at $233.2, down 1.44% over 24 hours, with technical indicators showing a bearish trend near key support at $228. The company reported mixed recent earnings, beating in Q1 2026 but missing in Q4 2025, with Q2 2026 results expected soon. Revenue has stabilized around $32.5B in 2025 after declines from 2022 peaks, while net margins compressed to 5.36%. Analyst sentiment remains positive with a 62.5% buy rating and $263.11 consensus target, supported by strong cash flow and a 53-year dividend growth streak.
NUE offers value with reasonable valuation multiples (P/E 22.89, P/S 1.55) and robust shareholder returns, but faces risks from steel demand volatility and margin pressure. The upcoming Q2 earnings report on July 27, 2026, will be critical for confirming growth trajectory amid economic uncertainties.
No Aura AI signal available yet.
Trailing returns across standard periods
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →